Topotecan for neuroednoctien cacner – pro
Literature supports the use of topotcan in second line treatment of neuroendocrine cancer. IN the 2014 study by Oldens, twenty-two eligible patients received a median of 2 courses [range1-6]. The authros conluded that topotecan monotherapy shows modest anti-tumor activity in heavily treated patients with progressive disseminated G3 neuroendocrine carcinomas.The 2015 study by Apostolis had similar findings.
Ron Basuroy et al, A Multimodal Approach to the Management of Neuroendocrine Tumour Liver Metastases International Journal of HepatologyVolume 2012 (2012)
Ingrid Holst Olsen et al,Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. J Cancer. 2014; 5(8): 628632.
Leonidas Apostolidis, Dirk Jaeger, Eva Caroline Winkler; Dep. of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University Hospitals Heidelberg, Heidelberg, Germany. Efficacy and toxicity of topotecan in pretreated metastatic extrapulmonary neuroendocrine carcinoma. J Clin Oncol 33, 2015 (suppl; abstr e15194)